- Home
- BEAM vs LXP Comparison
BEAM vs LXP Comparison
Compare BEAM & LXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- LXP
- Stock Information
- Founded
- BEAM 2017
- LXP 1993
- Country
- BEAM United States
- LXP United States
- Employees
- BEAM N/A
- LXP N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- LXP Real Estate Investment Trusts
- Sector
- BEAM Health Care
- LXP Real Estate
- Exchange
- BEAM Nasdaq
- LXP Nasdaq
- Market Cap
- BEAM 2.3B
- LXP 2.6B
- IPO Year
- BEAM 2020
- LXP 1993
- Fundamental
- Price
- BEAM $25.14
- LXP $49.16
- Analyst Decision
- BEAM Strong Buy
- LXP Buy
- Analyst Count
- BEAM 12
- LXP 3
- Target Price
- BEAM $48.09
- LXP $54.17
- AVG Volume (30 Days)
- BEAM 2.3M
- LXP 895.8K
- Earning Date
- BEAM 11-04-2025
- LXP 10-30-2025
- Dividend Yield
- BEAM N/A
- LXP 5.70%
- EPS Growth
- BEAM N/A
- LXP 487.65
- EPS
- BEAM N/A
- LXP 1.90
- Revenue
- BEAM $55,701,000.00
- LXP $364,335,000.00
- Revenue This Year
- BEAM N/A
- LXP N/A
- Revenue Next Year
- BEAM $19.01
- LXP $3.89
- P/E Ratio
- BEAM N/A
- LXP $25.89
- Revenue Growth
- BEAM N/A
- LXP 6.98
- 52 Week Low
- BEAM $13.53
- LXP $34.25
- 52 Week High
- BEAM $35.25
- LXP $52.52
- Technical
- Relative Strength Index (RSI)
- BEAM 58.18
- LXP 92.30
- Support Level
- BEAM $20.23
- LXP $44.17
- Resistance Level
- BEAM $22.72
- LXP $46.66
- Average True Range (ATR)
- BEAM 1.68
- LXP 1.54
- MACD
- BEAM 0.36
- LXP 1.07
- Stochastic Oscillator
- BEAM 97.41
- LXP 92.15
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.